Teresa Lanza di Scalea1, Katherine L Wisner. 1. Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. lanzadiscaleat@upmc.edu
Abstract
BACKGROUND: The prevalence and recurrence rates of postpartum depression (PPD) are 13 and 25%, respectively. Despite its detrimental impact on the health of the mother-infant dyad, there is a paucity of data in the literature regarding the efficacy of pharmacological treatment of PPD. OBJECTIVES: i) To review the literature on the use of antidepressants and hormonal supplements for the prevention and the treatment of PPD; ii) to give the authors' opinion on the current status of the pharmacological treatment of PPD; and iii) to discuss developments that are likely to be important in the future. METHODS: An electronic search was performed by using PubMed, Medline, and PsychINFO. Inclusion criteria were: i) empirical articles in peer-reviewed English-language journals; ii) well-validated measures of depression; and iii) a uniform scoring system for depression among the sample. RESULTS/ CONCLUSION: The electronic search yielded a total of 19 articles (12 on treatment and 7 on prevention of PPD) with the following study designs: eight randomized clinical trials (six using placebo control and two using active control groups), and 11 open-label studies. The selection of the specific antidepressant for a woman with PPD should derive from a personalized risk-benefit analysis.
BACKGROUND: The prevalence and recurrence rates of postpartum depression (PPD) are 13 and 25%, respectively. Despite its detrimental impact on the health of the mother-infant dyad, there is a paucity of data in the literature regarding the efficacy of pharmacological treatment of PPD. OBJECTIVES: i) To review the literature on the use of antidepressants and hormonal supplements for the prevention and the treatment of PPD; ii) to give the authors' opinion on the current status of the pharmacological treatment of PPD; and iii) to discuss developments that are likely to be important in the future. METHODS: An electronic search was performed by using PubMed, Medline, and PsychINFO. Inclusion criteria were: i) empirical articles in peer-reviewed English-language journals; ii) well-validated measures of depression; and iii) a uniform scoring system for depression among the sample. RESULTS/ CONCLUSION: The electronic search yielded a total of 19 articles (12 on treatment and 7 on prevention of PPD) with the following study designs: eight randomized clinical trials (six using placebo control and two using active control groups), and 11 open-label studies. The selection of the specific antidepressant for a woman with PPD should derive from a personalized risk-benefit analysis.
Authors: Cynthia L Battle; Caron Zlotnick; Teri Pearlstein; Ivan W Miller; Margaret Howard; Amy Salisbury; Laura Stroud Journal: Depress Anxiety Date: 2008 Impact factor: 6.505
Authors: Kimberly A Yonkers; Haiqun Lin; Heather B Howell; A Christopher Heath; Lee S Cohen Journal: J Clin Psychiatry Date: 2008-04 Impact factor: 4.384
Authors: Su-Chin Serene Olin; Bonnie Kerker; Ruth E K Stein; Dara Weiss; Emma D Whitmyre; Kimberly Hoagwood; Sarah M Horwitz Journal: J Womens Health (Larchmt) Date: 2015-11-18 Impact factor: 2.681
Authors: Julia Sacher; P Vivien Rekkas; Alan A Wilson; Sylvain Houle; Leslie Romano; Jinous Hamidi; Pablo Rusjan; Ian Fan; Donna E Stewart; Jeffrey H Meyer Journal: Neuropsychopharmacology Date: 2014-07-30 Impact factor: 7.853